Breast Cancer Risk Decreases with Less Exposure to Smoking

According to a new study, women that come from smoke-free homes and workplaces are less likely to develop or die from breast cancer.

The analysis, which was part of a study of health behavior at the Roswell Park Cancer Institute in Buffalo, New York, revealed that 20 percent of the decrease in breast-cancer death rates over the last few years came as a result of changes in smoke-free home and workplace regulations.

"While the evidence for secondhand smoke and breast cancer risk remains controversial, this study demonstrates a very strong inverse correlation. States with higher percentages of women working and living in smoke-free spaces have lower breast cancer rates," study author Andrew Hyland said in an institute news release.

"This study provides yet another reason for people to stop smoking and avoid secondhand smoke exposure," added colleague K. Michael Cummings.

This report will no doubt simply add to the confusion that currently exists regarding the true impact of smoking on potential breast cancer. What originally started out as a health debate, has slowly but surely devolved into a political debate which has serious ramifications for cigarette companies all over the United States.

This study is scheduled to appear in an upcoming issue of the journal Tobacco Control.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap